A limitation of this analysis is that we could not investigate vaccine

efficacy against asymptomatic influenza infections. However, LAIV efficacy estimates remained stable for moderate/severe and mild influenza illness; the point estimates for efficacy against mild influenza were always contained within the 95% confidence intervals of the efficacy estimates against moderate/severe influenza. These results also suggest that LAIV might also be similarly efficacious against asymptomatic www.selleckchem.com/products/Temsirolimus.html influenza infections. In summary, LAIV provided consistently high efficacy against moderate/severe and milder influenza illness compared with placebo in children >24 months of age. It also was consistently more efficacious than IIV. Efficacy against all influenza illnesses, regardless of severity, is critical to prevent influenza illness and transmission in the community. Contributors: Study concept and Libraries design was contributed by Dr. Ambrose. Acquisition of data was contributed by Drs. Ambrose, Belshe, and Wu. All the authors Selleck CHIR 99021 contributed to analysis and interpretation of

data, drafting of the manuscript, and critical revision of the manuscript for important intellectual content. The statistical analysis was contributed by Dr. Wu. All authors have seen and approved the final manuscript for submission. Financial disclosures: Drs. Ambrose and Caspard are employees of AstraZeneca, the parent company of MedImmune, Gaithersburg, MD and may hold stock or stock options. Dr. Wu was an employee of MedImmune at time of analysis. Dr. Belshe has received research support from MedImmune and served as a consultant for and served on speakers’ Ketanserin bureaus for

MedImmune and Merck. Funding/support: This research was sponsored by MedImmune. Role of the sponsor: Some authors are employees of MedImmune and contributed to the design of the study, the analysis and interpretation of the data, and in reviewing and approving the manuscript. Additional contributions: Editorial assistance was provided by Susan E. DeRocco, Ph.D. and John E. Fincke, Ph.D. of Complete Healthcare Communications, Inc. (Chadds Ford, PA) and funded by MedImmune. “
“Mycobacterium bovis belongs to the Mycobacterium tuberculosis complex of bacteria and is the main aetiologic agent of bovine tuberculosis (BTB) as well as being responsible for a proportion of cases of human tuberculosis (TB). Despite the application of the test and slaughter policy, the incidence of BTB in GB has increased steadily since the 1980s and this is thought to be due to the existence of a wildlife reservoir [1]. Hence, vaccination is being considered as an additional tool to contribute to the control of BTB [2]. The live attenuated strain M.